As a clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to optimize and develop drug candidates to treat ulcerative colitis and other inflammatory diseases (ABX464), HIV (ABX464), and liver cancer (ABX196). Our mission is to utilize Abivax’s drug development platforms to bring innovative and effective solutions to patients in these therapeutic areas with significant unmet needs.
Allecra’s mission is to contribute to the global effort to combat anti-biotic resistance. Antibiotic resistance is widespread and growing exponentially. Allecra’s contribution is to develop new treatments which overcome emerging resistance mechanisms, thereby saving lives of patients whose infections will otherwise be inadequately treated.
Allecra has a novel β-lactamase inhibitor administered in a fixed dose combination with cefepime as IV infusion in Phase 3 clinical development. The product is designed to overcome resistance of Gram-negative hospital pathogens harboring extended spectrum β-lactamases (ESBLs) and has demonstrated to have a carbapenem-sparing activity. Ph 3 results in Complicated Urinary Tract Infections (cUTI) as lead indication are expected in Q4 2019. The program has been developed as the new empirical therapy for serious hospital infections where ESBLs are suspected, replacing current standard of care.
Allecra Therapeutics is situated in the BioValley Life Sciences region in the Upper Rhein valley whichencompasses northwest Switzerland, southwestern Germany and the Alsace region of France. http://allecra.com/
AMYRA Biotech AG
AMYRA is developing therapeutic product applications for the treatment of celiac disease and gluten sensitivity, which represent major public health issues.
The global prevalence is 1-3% for celiac disease and 6-10% for gluten sensitivity, resulting in huge markets, estimated at USD 8 bn and USD 15 bn, respectively, which are basically untapped.
Both conditions are triggered by the ingestion of gluten, which is ubiquitously present in the Western diet and thus almost impossible to avoid.
Anagenesis Biotechnologies COMPANY PROFILE Anagenesis Biotechnologies is a preclinical-stage stem cell-based company focused on developing novel treatments for muscle degenerative diseases and type 2 diabetes. Anagenesis Biotechnologies secured private investments from the AFM (French muscular dystrophy association) to develop applications in the skeletal muscle therapeutic area, from Cap Innov’Est and form the Boehringer Ingelheim Venture Fund. Anagenesis Biotechnologies aims to complete now a series A funding of at least 15 M€ under the lead of the Boehringer Ingelheim Venture Fund.
Anima Biotech is advancing Translation Control Therapeutics, the first and only platform for the discovery of small molecule drugs that specifically control mRNA translation as a new strategy against hard and undruggable targets in many diseases.
Anima’s proprietary technology enables visualization and monitoring of target protein translation via pulses of light emitted by ribosomes. The fully automated high-throughput screening system discovers small molecules that modulate the light, as they decrease or increase the target protein’s production. The platform integrates proprietary technologies in biology, bioinformatics, image analysis, big data analysis and artificial intelligence algorithms in a cloud computing software architecture.
Anima is developing an internal pipeline across multiple therapeutic areas with high unmet need and hard targets. Current programs are in Fibrosis (inhibiting the synthesis of Collagen type I), Viral infections (Respiratory Syncytial Virus – interfering with viral protein synthesis), Oncology (C-Myc translation inhibitors) and Huntington's disease (monitoring mutant Huntingtin translation pausing).
Anima’s Translation Control Therapeutics platform is strategically designed for partnering with Pharma. The power of Anima’s approach was solidified with a $1B+ collaboration with Lilly for the discovery and development of translation inhibitors of several targets. Anima’s technology has been further validated by 5 granted patents, 14 peer reviewed publications and 17 scientific collaborations.
At ARTIDIS AG, we are committed to radically improving health outcomes by harnessing the power of nanotechnology and innovation. ARTIDIS™, our innovative new nanomechanical biomarker tool for cancer diagnosis and treatment, seeks to improve people’s lives by dramatically reducing the time it takes to accurately diagnose breast cancer – from a period of days or weeks to as little as three hours —thereby substantially reducing anxiety and time lost. ARTIDIS™ will also improve lives by facilitating personalized treatments, based on precise nanopalpation measurements of cancer aggressiveness and correlation to individuals’ specific medical data and histories.
We believe that same-day diagnosis and individually-based treatment are the future in the era of value based health care. We also believe that medicine should be informed by the very latest discoveries in cutting-edge research. Accordingly, we are working on applications for our technology to the treatment of diseases beyond breast cancer. At ARTIDIS AG, we are committed to innovation and excellence, in order to bring the future of health care to people today.
ATRIVA aims to develop new antiviral therapies against different respiratory viral infections. Founded in 2015, ATRIVA attracted seasoned experts in virology and drug development to form a unique venture targeting the fast and successful validation of a novel approach to fight infectious diseases Inhibitors of certain cellular signaling pathways, the so called “MEK-Inhibitors”, have shown a superior antiviral activity by blocking viral replication. This creates an unprecedented potential for truly efficacious and safe therapeutics against numerous viral infections.
ATRIVA closed a seed financing of €3 Mn in late 2016. The proceeds of this allows the company to reach clinical development with its lead project ATR-002 for influenza in high-risk patients. We invite you to explore our approach and pipeline presented on this website and encourage you to contact us directly.
BAYOOMED is the medical software division of BAYOONET Inc. Here we combine medical professional know-how with our software development expertise. We serve more than 800 clients from the pharmaceutical and medical technology sector, and we specialize in the development of medical (standalone) software and medical apps (iOS, Android, Windows 8) in accordance with IEC 62304, ISO 13485, ISO 14971 and EN 62366. We support our clients through all product lifecycle phases:
Based on its insights in immunology, cancer biology and antibody biology, BioInvent aims to develop cancer immunotherapies to improve the quality of life for cancer patients.
BioInvent's current operational activities are focused on:
Progressing and expanding the clinical development of its lead antibody BI-1206 for treatment of haematological cancers.
Developing pre-clinical first-in-class antibodies targeting tumour-associated myeloid cells in collaboration with Pfizer.
Advancing three compounds into clinical programs in solid cancer: anti FcγRllB antibody in combination with anti-PD1 antibody – projected start phase l/lla in H1 2019; BI-1607 (an anti FcγRllB antibody) in combination with check point inhibitor – projected start phase l proof of concept trial in H2 2019; BI-1808 (anti-“EmergingTNFRS” antibody), as single agent and in combination with anti-PD1 antibody – projected start phase l in H1 2020. Advancing its pre-clinical Treg immuno-oncology programmes identifying antibodies to novel targets and pathways, as well as differentiated antibodies with new mechanisms-of-action to validated targets. Intensify the collaboration with Transgene to start the development of oncolytic virus (OV) candidates encoding a validated anti-CTLA-4 antibody sequence - potentially with additional transgenes - aimed at treating solid tumors. Developing TB-403, in collaboration with Oncurious, as a potential treatment for paediatric brain cancers.
The Swiss biopharmaceutical company BioVersys focuses on research and development of small molecules which switch off drug resistance against existing antibiotics. With the company’s award-winning TRIC technology (Transcriptional Regulator Inhibitory Compounds) it will be possible to restore the efficacy of established antibiotics. By this, BioVersys addresses the high medical need for new treatments against life-threatening bacterial infections that emerged in recent years due to the resistance of bacterial strains against existing antibiotics. BioVersys' compounds will be used in combination with existing antibiotics, thereby renewing efficacy as well as intellectual property for the established drug. The current research focus is Nosocomial Infections (hospital infections) and Tuberculosis. In collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille, BioVersys is developing a preclinical candidate against tuberculosis.
Over the last three decades, the number of newly approved antibiotics has steadily declined. At the same time, resistance against existing drugs has become more and more prevalent. Antibiotic resistance is recognized by the WHO as a major public health concern as exemplified by its recently released global report (click HERE for access). BioVersys has a pipeline of promising compounds that address this concern. The company is currently at preclinical stage with proof-of-concept in animals already demonstrated.
We are a group of individuals who know that there is a better way to develop drugs. Our business model and broad, science-based portfolio has attracted some of the brightest minds in drug development. Our team brings together more than 300 years of pharmaceutical industry experience.
BrainStorm Cell Therapeutics (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as:
Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease and
Motor Neuron Disease)
Our platform technology, NurOwn®, uses proprietary culture conditions to induce mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs) known to promote the survival of neurons. Our research efforts have shown that these MSC-NTF cells might be an effective tool for battling neurodegenerative diseases.
Cue Biopharma is committed to bringing selective immune modulation to patients through our Cue Biologics platform. Our talented scientists are led by an experienced management team and supported by leading scientific and clinical advisors with deep expertise in the design and clinical development of protein biologics to treat cancer and autoimmune diseases. Together, we are developing novel, targeted therapies aimed at overcoming many of the challenges facing prevailing immunotherapeutics. We are headquartered in Kendall Square, Cambridge, MA.
The management of Emerald Health Pharmaceuticals (EHP) believes that cannabinoid analogues have the potential to be developed into safe, effective prescription pharmaceutical drugs. The potential ability of cannabis to treat a broad range of health problems and diseases mirrors the wide distribution of cannabinoid receptors present throughout our bodies. This system is called the endocannabinoid system and is responsible for creating homeostasis (i.e., “balance”) in the body and for reducing inflammation, which is the primary cause of many diseases afflicting millions of people worldwide.
EHP leverages the extensive life-science experience of its founders and management, as well as the expertise of its partners, to produce patented new chemical entities (NCEs) derived from cannabis, and to develop the most promising of these NCEs into pharmaceutical drug candidates. The Company currently has two NCEs in preclinical development. One of these NCEs (EHP-101) is derived from cannabidiol (CBD) and is being developed for the treatment of multiple sclerosis (MS) and scleroderma, also known as systemic sclerosis (SSc). The second NCE (EHP-102) is derived from cannabigerol (CBG), and is being developed for the treatment of Huntington’s Disease (HD) and Parkinson’s Disease (PD).
EpimAb Biotherapeutics is a privately owned biopharmaceutical R&D company based in Shanghai with a proprietary, unique and efficient technology called FIT-Ig® (Fabs-In-Tandem Immunoglobulin) that generates bispecific molecules with antibody-like properties. With this innovative platform, EpimAb is creating a potentially game-changing pipeline of its own novel bispecific antibody therapeutics focused around immuno-oncology and other areas of high value to patients.
Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary spherical nucleic acid (SNA™) architecture is designed to unlock the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address inflammatory diseases, genetic disorders and oncology. Exicure is based outside of Chicago, IL.
SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.
SNA™ technology originated in the lab of Professor Chad A. Mirkin at the Northwestern University International Institute for Nanotechnology. Exicure's intellectual property portfolio includes over 135 pending patent applications and over 60 allowed or issued patents. These filings impact numerous jurisdictions worldwide, and they cover a range of inventions, including fundamental nanoparticle manufacturing breakthroughs and numerous application-specific improvements.
Forendo Pharma is a clinical stage drug development company, with core competences in modulating tissue specific hormone mechanisms. The company’s pipeline includes HSD17B1 inhibitor (phase I) for the treatment of endometriosis; dual HSD inhibitors (discovery) for the treatment of broader gynecological conditions; and Fispemifene (phase 2), a novel SERM for the treatment of male urological conditions. The company was founded in 2013 and is based in Turku, Finland.
GamaMabs is a privately held immuno-oncology biotechnology company specialized in the development of optimized monoclonal antibodies (mAb).
Its lead program is GM102 (formerly 3C23K), a mAb targeting the receptor of the anti-Müllerian hormone (AMHR2) in gynecological cancers, currently in phase Ia/Ib stage. GM102 has increased tumor cell killing properties through the activation of immune system cells, thanks to its EMABling® glyco-engineering technology.
Founded in June 2013 in Toulouse (France), GamaMabs employs 7 professionals with a sound and successful experience in preclinical and clinical development up to registration.
GamaMabs has established collaborations with leading academic and private partners in order to develop its programs, such as Institut Gustave Roussy, Institut Curie, Institut Cochin, Institut de Recherche en Cancérologie de Montpellier (IRCM) or Mass General Hospital (Boston).
GamaMabs values high-potential technologies initially developed by LFB BIOTECHNOLOGIES, a French Biopharma specialized in Hemostasis and Immunological Disorders. LFB developed two original patented platforms for the generation of mAbs with high efficiency (EMABling®) and/or long duration of action (HuMabFc), as well as a pipeline of several products stemming from those technologies.
For strategic reason LFB decided to transfer some assets and rights to use its mAbs platforms and mAbs Oncology projects to GamaMabs. The main objective of GamaMabs is to develop its mAbs up to the stage of Clinical Proof of Concept.
2004 - Prof. Bernard BIHAIN, Doctor of Medicine, Dr. Virginie OGIER, and Dr. Sandrine JACQUENET create the company GENCLIS as a contracted clinical research company. GENCLIS generates between 1 and 1.2 million Euros in revenue, with a profit greater than 20%.
2006 - GENCLIS organizes its first capital increase, in order to develop its own range of products. CM-CIC Investissement and the Institut Lorrain de Participation are involved in the capital increase.
2007 - GENCLIS is the first company to achieve the production and clinical validation of a recombinant test for the diagnosis of food allergy.This product changes clinical practice in regards to the diagnosis of peanut allergy and is licensed to PHADIA (now THERMO FISHER).The same year, GENCLIS files a patent protecting its discovery of transcription infidelity.
2008 - GENCLIS undertakes a program of translational research, aimed at establishing the clinical relevance of its discovery of RNA sequence heterogeneities, or RNA-DNA differences (RDDs).
2010 - GENCLIS competes and is awarded first prize (EUR 1 million) on behalf of the fondation INNABIOSANTE for its discovery of RDDs.
2011 - The concept of differences between DNA and RNA sequences is established and confirmed by several independent academic groups.
2013 - The National Institute of Health (NIH) grant GENCLIS unlimited access to clinical and sequencing data developed under the framework of The Cancer Genome Atlas (TCGA) program (TCGA Database). GENCLIS obtains the first statistical evidence of a strong association between RDD levels and the severity of triple-negative breast cancer (TNBC).
2014 - GENCLIS begins marketing a range of allergenic products through partnerships with Hycor Biomedical (human market) and Galileo Diagnostics (veterinary market).
2015 - The measurement of RDD levels opens new perspectives in the detection of the severity of all major cancers. The first range of SeveridiaTM products aims to predict the risk of recurrence of three cancers – TNBC, clear cell renal cell carcinoma, and bladder carcinoma – which are frequently characterized by the absence of recurrence after resection.
IGEM Therapeutics is a UK Immuno-Oncology company developing novel IgE antibodies to treat cancer. IgE has evolved to kill tissue-dwelling multicellular parasites endowing it with several key features that make it ideal for the treatment of solid tumours which also mostly reside in tissue. The epsilon constant region of IgE binds very tightly to its cognate receptor (FcεRI) on the surface of immune effector cells including macrophages, monocytes, basophils and eosinophils. This interaction is up to 10,000 fold greater than the gamma chain of IgG has for its equivalent receptor and this results in the majority of IgE molecules being permanently attached to the surface of immune effector cells. The latter are therefore primed and ready to destroy cells expressing the antigen recognised by the IgE. As a result, IgE is able to permeate tissues more effectively than IgG and stimulate significantly greater levels of both ADCP (antibody-dependent cell-mediated phagocytosis) and ADCC (antibody-dependent cell-mediated cytotoxicity), the two main mechanisms by which immune effector cells can kill tumour cells. IgE also has a significantly longer tissue half life than IgG (2 weeks versus 2 – 3 days) which also suits it for a role in the destruction of solid tumours.
The company’s lead programme targets the folate receptor alpha (FR alpha) and an anti-FR alpha IgE antibody is currently in a phase 1/2a trial to treat ovarian cancer. This is the world’s first IgE therapeutic to enter the clinic.
IGEM is also developing a novel antibody platform technology based on protein and glyco-engineering of the epsilon constant region.
Imcyse is pioneering the development of a new class of active, specific immunotherapeutics: ImotopesTM. Imcyse’s new technology platform is based on the discovery of modified synthetic peptides to block the immune processes causing immune-mediated diseases. Imcyse’s ImotopesTM offer the possibility to cure severe chronic diseases for which there is no satisfactory therapeutic alternative. The technology can also prevent the immunogenic responses that weaken the efficiency of chronic therapies.
Our vision is to become a major player in active specific immunotherapy for the curative treatment of autoimmune and allergic diseases.
IO Biotech is a clinical stage biotech company developing disruptive immune therapies for immunological treatment of cancer. Our pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of T cells that are specific for immune inhibitory molecules.
IO Biotech has achieved a proven track record of progressing compounds to the clinic, and has two lead immune modulating anti-cancer therapies targeting IDO and PD-L1 in clinical development and several compounds finalizing preclinical phase.
IO Biotech has an experienced management team within immuno-oncology fields and a world-class advisory board.
Immune System Key Ltd. (ISK) is a privately held company that was founded in 2005 by Prof. Uziel Sandler and Dr. Yoram Devary.
The company is engaged with developing of its drug candidate Nerofe TM. Nerofe TM acts through a novel MOA that serves as the basis for the personalized anti-cancer immunotherapy technology developed by ISK Ltd. Our anti-cancer immunotherapy technology synergizes well with anti-PD1/PDL1 technology.
The company has successfully finished Phase1 trial and is now aiming three Phase 2 clinical trials in the USA.
NerofeTM was granted by the FDA with orphan drug designation for AML treatment. The company holds 3 worldwide patents on the molecule and applications.
We are looking for collaborations and investments to keep on developing our anti-cancer technology
InCarda Therapeutics, Inc. is a privately-held, clinical-stage biopharmaceutical company pioneering a novel approach of treating cardiovascular conditions by the inhalation route. The advantage of inhalation is that it delivers medicine in the “first pass” to cardiac tissue, presenting a small, but effective dose of drug directly to affected regions of the heart. This permits rapid-onset, lower off-target tissue exposure of the drug, lower continued/prolonged exposure to cardiac tissue and, more importantly, can be patient self-administered anywhere PAF episodes may occur.
The lead product under development is an inhaled therapy to treat paroxysmal atrial fibrillation (PAF), a widespread atrial arrhythmia. InCarda employs a de-risked approach by using approved drugs with a long history of efficacy and safety in a new dosing paradigm.
We are a team of highly-experienced, passionate teammates who have a strong track record of development. We are also supported by a world-class group of experts and advisors.
Medherant is developing a pipeline of products for pain and neurology indications, based on its next-generation TEPI-Patch® transdermal drug technology. The company also formulates client molecules in this unique solvent-free drug-in-adhesive system. Medherant was founded by Professor David Haddleton and the University of Warwick to develop and commercialise novel technologies for delivery of drugs via the skin using their world-leading expertise in bioadhesives and polymer chemistry. The Company is based on the University of Warwick Science Park in Coventry (UK). Medherant has received investment from Mercia Fund Management and others. Delivery of drugs using patches that are applied to the skin provides better control of the dose than with gels, ointments and creams. However, the currently available technologies limit the types of drugs that can be used and the quantities that can be loaded into the patch. Medherant’s TEPI Patch® is formulated with a novel polymer adhesive which has been exclusively licensed from Bostik. The drug to be delivered is mixed with the adhesive to form a thin, flexible, single layer patch. One of the key advantages of the TEPI Patch® technology is that a greater quantity of drug can be blended with the adhesive. This enables lower potency drugs to be formulated as a patch and provides the opportunity to increase the dose of drugs already administered via a patch or reduce patch size. The TEPI Patch® also provides a better experience for the user as it does not leave a residue around the patch – referred to as ‘cold flow’ – and has excellent adhesion whilst still being easy and painless to remove. Medherant is developing its own TEPI Patch® products in the fields of pain management and CNS disorders, and is working with third parties to apply the technology to their drugs. The Company expects to earn revenues from licensing products that it has developed to pharmaceutical companies and through collaborative development projects leading to potential technology licences.
Our pipleline includes drugs aimed at first-in-class targets that are synthetically lethal with the loss of the following metabolic enzymes: Fumarate Hydratatse (FH), Succinate Dhydrogenase (SDH) and Methylthioadenosine Phosphorylase (MTAP). Although SDH and FH are “housekeeping genes”‘ with key bioenergetic roles, they are also known to be tumor-suppressing genes. The loss of their function results in cancer, specifically in the kidney and in the GI tract. MTAP function is lost in about 15% of all cancers. This percentage grows to 55% of Glioblastoma and up to 25% Pancreatic Adenocarcinoma, two especially aggressive and hard to treat cancers.
MGC Pharmaceuticals Ltd (ASX: MXC OTCUS: MGCLF) is a European-based specialist Medical Cannabis company and an international pioneer in Phytocannabinoid-based medicine within the biopharmaceutical industry.
Heralding countless years of practical, scientific and business experience, MGC Pharma’s founders are all prominent leaders in the Global Medical Cannabis industry.
MGC Pharma’s principal business goal is to produce and supply high qualityPhytocannabinoid based pharmaceutical products (Phytomedicines and Phytotherapeautics) for the medical markets of Europe, North America and Australasia.
Our vaccines are designed to induce protection against early transmission and infection, focusing both on the mucosal immune response as a first-line defense and the systemic humoral (blood) immune response, which, for some pathogens, may be essential for the development of an effective prophylactic vaccine. Our unique approach has resulted in the development of a rich pipeline of vaccine candidates for HIV-1/AIDS, intra nasal Influenza, Malaria, Chikungunya and the Respiratory Syncytial Virus (RSV) vaccine. Our delivery platform is being validated through partnership with leading pharmaceutical or research organisations, including Sanofi, PATH-MVI and the Bill and Melinda Gates Foundation. Mymetics Corporation (OTCQB: MYMX) is a Swiss based biotechnology company, with a Research Lab in the Netherlands. The company is registered in the US and trades on the OTCQB. www.mymetics.com
ORYZON GENOMICS S.A. [BME:ORY]
Oryzon is a public clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics.
From its founding in 2000 through 2008, the company focused its efforts in grow¬ing a functional genomics platform business model, In 2008, with the acquisition of Crystax Phar-maceuticals, we started our drug discovery programs in oncology and neurode¬generative diseases. Our business model is to develop our proprietary drug candi¬dates till mid clinical stage, at which point it is decided on a case-by-case basis to either keep the development in-house or to partner or outlicense the compound for late stage development and commercialization.
Oryzon is listed on the Spanish Stock Exchange since December 2015 (ORY, ISIN Code: ES0167733015). In the period 2015-2016, the company raised €32M, with ad¬ditional Pipes in 2017 (€18.2M) and 2018 (€13M) where the company incorporated specialized investors from US and Europe. The company has a broad and growing portfolio, with two compounds in clinical trials, Iadademstat (ORY-1001), a highly potent and selective LSD1 inhibitor that has been granted orphan-drug status by EMA, in Phase IIA in oncology, and Vafidem¬stat (ORY-2001), a LSD1/MAO-B inhibitor , also in Phase IIa, dual for the treatment of mild to moderate Alzheimer’s disease, multiple scle¬rosis. Vafidemstat is al being explored in a basket trial to treat aggressiveness in psychiatric conditions like ASD, ADHD and BLP and other neurodegenerative diseases. The company has another compound ready to start Phase I, ORY-3001, a selective LSD1 inhibitor for the treatment of non-oncological diseases, and additional earlier programs in other cancer indications.
From 2014 to 2017 the company had a collaboration with Roche relating to our lead oncology program and received +$23M. This asset is now being developed by Oryzon. The company has also obtained competitive US and European grants in the amount of €8M to support the development of Vafidemstat (ORY-2001) since the start of our CNS research. The company has a seasoned executive management with vast experience in the industry.
Founded in April 2014 in Grenoble (France) as a spin-off of the French Blood Bank (Etablissement Français du Sang, EFS), PDC*line Pharma is a Belgian-French biotech company that is developing a novel class of off-the-shelf cancer immunotherapies based on a proprietary Plasmacytoid Dendritic Cell line (PDC*line) pre-loaded with peptides that are derived from target tumor antigens. Based on a robust preclinical package and a first-in-human phase Ib feasibility study in melanoma, PDC*line Pharma is focusing on lung cancer with a new candidate in early clinical development (PDC*lung) and neoantigens (PDC*Neo). PDC*line Pharma comprises a team of highly skilled professionals based in Liège (Belgium) and Grenoble (France). PDC*line Pharma comprises a team of 17 persons, has raised nearly €15 M in equity and non-dilutive funding.
Perora GmbH, a biotechnology company, develops a polymer-based fat-binding medical device as a platform for weight management and obesity treatment. The company was incorporated in 2013 and is based in Heidelberg, Germany.
Pharmaleads aims to provide patients suffering from severe chronic and acute pain with improved pain relief without the side effects associated with other classes of analgesics.
Based on years of experience in the design of highly potent and specific inhibitors of enkephalinases, Pharmaleads has developed a new class of analgesics called DENKIs (Dual Enkephalinases inhibitors). These small molecules are able to provide patients with local and sustainable pain relief.
Pharmaleads’ DENKIs are first-in-class drugs with a novel mechanism of action tackling pain by using endogenous enkephalins, natural peptides that specifically bind to pain-related opioid receptors to naturally modulate pain without the side effects observed with exogenous opioid drugs that also bind to other opioids receptors, not involved in pain control, triggering multiple side effects.
Pharmaleads believes its products can change the lives of the many patients who are in need of improved treatment options for their chronic and/or acute pain, and could offer healthcare providers with an improved pain management option that helps address the opioid epidemic.
We aim to become a leading pharma company focused on antibiotics and specialty diseases
We are a clinical stage biopharmaceutical company based in Allschwil, Switzerland, and are focused on the discovery and development of antibiotics and other specialty pharma products for severe or life-threatening diseases.
Polyphor was founded in 1996 and is a clinical stage biopharmaceutical company based in Allschwil, Switzerland, near Basel. It focuses on the development of macrocycle drugs that address antibiotic resistance and improve therapy outcomes in cancer.
STALICLA is an autism spectrum disorder (ASD) focused, data guided, drug development biotech company incorporated in May 2017. Through an innovative systems biology-based platform (DEPI), STALICLA has been able to identify non-behavioral subgroups of patients with idiopathic ASD and corresponding first-in class treatment candidates, thus pioneering personalized medicines for ASD.
Q1 2018 successful closure of CHF 4M seed round
Development of a strong ecosystem with Key Opinion Leaders in the field of ASD
February 2018, STALICLA listed among the top 50 startups in Switzerland (Business magazine BILAN classification)
March 2018, first clinical validation of the ASD Ph1 subgroup through observational clinical trial at the Greenwood Genetic Center (SC, USA)
April 2018, listing of STALICLA among emerging biotech to follow by Canaccord Genuity, a global financial services firm with strong focus on healthcare sector
May 2018, official launch of STALICLA’s clinical development program
July-August 2018, results supporting specific biological profile in ASD phenotype 1 vs other patients with ASD vs controls. Potential for first in class biomarker in idiopathic Autism Spectrum disorder
September 2018, positive EPO Search Report with “intention to grant” for STP1 COM patent. Operating parallel EU - US and international filling strategy.
October-November 2018, Incorporation of STALICLA’s Computational Systems Biology physical HPC unit in Barcelona, Spain – incl. 4 FTE computational biology data scientists.
November 2018, international patent applications, request for examination of the STP1 COM patent in USA, EU and other countries, filling new EU patent application and US provisional patent on specific metabolomic profile of ASD Ph1
November 2018, first results supporting efficacy of STP1 on metabolomic profile of ASD Ph1 patients
December 2018. final closure of STALICLA Series A1 for a total amount of CHF 10 M
We develop innovative therapies for the treatment of cancer and other significant diseases
Symphogen is a clinical-stage antibody oncology-focused company with a differentiated product pipeline and significant commercial opportunities. Our pre-clinical and clinical pipeline is well suited for a precision-medicine approach by addressing well-defined, biomarker-selected patient populations.
Two To Biotech Ltd. is a privately held biotech company established in 2007 engaged with the discovery of novel human peptide hormones and development of mAb against novel human targets. The peptide hormones we have discovered are for treatment of oncology indications and some for treatment of diabetes and other metabolic disorders.
The different peptide hormones were discovered by using the company's revolutionary technology platforms for the discovery of novel human peptide hormones, receptors, and enzymes. Our technologies are the first in the world that allows 3D-protein structure screening of the human genome, so we are not limited to any sequence. This approach allowed us to identify many novel proteins never discovered.
We are looking for collaborations and investments to discover and develop new targets in the area of immune regulation of cancer, regulation of body weight and metabolism.
UGISense AG is a biotech company dedicated to developing new and innovative antisense therapeutic agents in collaboration with partners from the industry and academia. The developments are made on the basis of a proprietary platform technology, i.e. the UgimeresTM. The company, which was first established in 2016, is being financed by private investors and has been accredited by the Federal Office of Economics and Export Control (BAFA) (within the scope of their Funds for Venture Capital program).
VAXIMM is a privately held, clinical stage, Swiss/German biotech company developing oral T-cell immunotherapies for patients suffering from cancer.
VAXIMM’s technology is based on first-in-class oral T-cell activators using modified attenuated bacteria that can be readily adapted to target a wide range of cancer-related antigens.
The Company’s lead product candidate, oral VXM01, activates killer T-cells targeting tumor vasculature and certain immune-suppressive cells, thereby increasing immune cell infiltration in solid tumors.
VXM01 is currently in clinical development for several tumor types, including pancreatic, colorectal and brain cancer.
The Company has several additional product candidates at various stages of preclinical development targeting a variety of tumor targets and neoantigens.
VAXIMM has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. to evaluate avelumab, a human anti-PD-L1 antibody, in combination with VXM01 in glioblastoma and colorectal cancer. The Company also has entered into a collaboration agreement with China Medical System Holdings (CMS), granting CMS full rights in China and other Asian countries (excluding Japan) to VAXIMM’s existing programs.
VAXIMM’s investors include BB Biotech Ventures, BioMed Partners, CMS, M Ventures and Sunstone Capital.
VAXIMM AG is headquartered in Basel, Switzerland. Its wholly owned subsidiary, VAXIMM GmbH, located in Mannheim, Germany, is responsible for the Company’s development activities.